期刊论文详细信息
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 卷:82
Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials
Article
Gold, Linda Stein1  Del Rosso, James Q.2  Kircik, Leon3  Bhatia, Neal D.4  Hooper, Deirdre5  Nahm, Walter K.6  Stuart, Iain7 
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] JDR Dermatol Res Thomas Dermatol, Las Vegas, NV USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Therapeut Clin Res, San Diego, CA USA
[5] Delricht Res, New Orleans, LA USA
[6] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[7] Foamix Pharmaceut Inc, Bridgewater, NJ USA
关键词: double-blind clinical trial;    facial;    minocycline;    papulopustular rosacea;    phase 3;    topical foam;   
DOI  :  10.1016/j.jaad.2020.01.043
来源: Elsevier
PDF
【 摘 要 】

Background: Efficacious topical medications for rosacea are needed. FMX103 1.5% is a novel topical minocycline foam that may have therapeutic benefits in treating rosacea while minimizing systemic adverse effects due to its topical route of delivery. Objective: To determine the efficacy, safety, and tolerability of 12 weeks of treatment with FMX103 1.5% topical minocycline foam for papulopustular rosacea. Methods: Two 12-week, phase 3, randomized, multicenter, double-blind, vehicle-controlled, 2-arm studies were performed in patients with moderate to severe papulopustular rosacea. Results: Participants who received FMX103 1.5%, versus control individuals treated with vehicle, exhibited a significantly greater reduction in the number of inflammatory lesions (FX2016-11: -17.57 vs -15.65; P =.0031; FX2016-12: -18.54 vs -14.88; P < .0001) and higher rates of Investigator Global Assessment treatment success (FX2016-11: 52.1% vs 43.0%; P =.0273; FX2016-12: 49.1% vs 39.0%; P =.0077). No serious treatment-related treatment-emergent adverse events occurred. Limitations: The generalizability of these data from a controlled clinical trial should be examined in a real-world setting. Conclusions: FMX103 1.5% was efficacious for moderate to severe papulopustular rosacea and maintained a favorable safety profile.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jaad_2020_01_043.pdf 1176KB PDF download
  文献评价指标  
  下载次数:24次 浏览次数:0次